[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Fourth Affiliated Hospital of Zhejiang University School of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":556},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,51,0,25,[9,47,71,99,120,140,160,183,203,220,247,270,292,317,336,359,379,396,412,428,447,469,489,508,536],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642298","bone-management-in-pregnancy-outcomes-in-epilepsy-100642298",false,"NCT07651709","Bone Management in Pregnancy Outcomes in Epilepsy","Bone Health Management on Pregnancy Outcomes in Women With Epilepsy: Randomized Study","Inclusion Criteria:\n\n* Diagnosis of focal or generalized epilepsy as defined by the International League Against Epilepsy.\n* Women of childbearing age, aged ≥18 years, planning pregnancy or in early pregnancy (≤16 weeks gestation, confirmed by last menstrual period or ultrasound) - single pregnancy.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Pre-existing conditions affecting bone metabolism: primary hyperparathyroidism, Paget's disease, multiple myeloma, chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin), cirrhosis (Child-Pugh B\u002FC), or untreated hyper\u002Fhypothyroidism.\n* History of metabolic complications: hypercalcemia (serum Ca²⁺ \\>10.5 mg\u002FdL), nephrolithiasis, or granulomatous diseases.\n* Recent\u002Fcurrent use of bone-modifying drugs: bisphosphonates, glucocorticoids (≥5 mg\u002Fday prednisone equivalent for \\>1 month), or loop diuretics within the past year.\n* Ultrasound shows fetal malformation.\n* Presence of other severe systemic diseases deemed unsuitable for study participation by the investigator.",true,"FEMALE","18 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is aimed to evaluate the efficacy of bone health management in improving pregnancy outcomes among WWE, and establish evidence-based vitamin D supplementation strategies for childbearing-age WWE.",[28,29,30],"Epilepsy","Pregnant Woman","Bone Health",[32,33],"epilepsy","pregnancy","RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":22},"2026-06",{"date":42,"type":22},"2035-01",{"name":44,"class":45},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":46},"100635838","a-prospective-single-centre-observational-cohort-study-on-the-efficacy-and-safety-of-bacterial-lysate-om-85-in-combination-with-antihistamines-for-the-treatment-of-chronic-spontaneous-urticaria-csu-100635838","NCT07557888","A Prospective, Single-centre, Observational Cohort Study on the Efficacy and Safety of Bacterial Lysate (OM-85) in Combination With Antihistamines for the Treatment of Chronic Spontaneous Urticaria (CSU)","A Prospective Clinical Study on the Efficacy and Safety of Bacterial Lysate (OM-85) Combined With Antihistamines in the Treatment of Chronic Spontaneous Urticaria (CSU): A Single-Centre, Observational, Cohort Study","Inclusion Criteria:\n\n1. The participants were fully informed of the purpose, procedure and risks of the study and voluntarily signed the informed consent form.\n2. Aged 18 to 65 (inclusive), no gender restrictions.\n3. Meets the CSU diagnostic criteria, with a disease duration of ≥6 weeks.\n4. Antihistamine resistance: Regular use of a standard dose (as recommended in the package leaflet) of a second-generation H1 antihistamine (e.g. desloratadine 5 mg, levocetirizine 5 mg, etc.) for at least 2 weeks prior to screening, but with symptoms still not effectively controlled. Defined as: a UAS7 score of ≥7 within 7 days prior to the screening visit (V1) and baseline visit (V2).\n5. Agree to maintain the type and dose of the baseline antihistamine throughout the trial.\n6. Agree not to consume any products that may significantly affect the gut microbiota during the trial (such as yoghurt containing probiotics, or probiotic\u002Fprebiotic supplements).\n7. At the baseline visit, the treatment regimen was clearly defined, and exposure status (OM-85 exposure group or non-exposure group) could be determined based on actual prescriptions and medication records.\n\nExclusion Criteria:\n\n1. Special types of urticaria: These primarily include physical urticaria (such as artificial urticaria, cold contact urticaria and cholinergic urticaria), urticarial vasculitis, and angioedema caused by hereditary or acquired C1 esterase inhibitor deficiency;\n2. Systemic use of glucocorticoids (oral or injectable) within the four weeks prior to screening;\n3. Exclude patients who have used immunosuppressants (such as cyclosporine, methotrexate, or Tripterygium wilfordii) within the previous four weeks;\n4. Exclude patients who have used biologics (such as omazulimab, dupilumab, etc.) within the previous three months;\n5. Exclude those who have used bacterial lysates (such as Panfuxu or Pidomod) or received vaccinations within the past three months;\n6. Key exclusion criteria for the microbiome study: use of oral or intravenous antibiotics within the four weeks prior to screening, or continuous use of probiotic supplements for more than one week.\n7. Patients with severe systemic autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.) may interfere with the assessment of immune mechanisms;\n8. A history of serious liver, kidney, heart, lung or blood disorders, or malignant tumours;\n9. Individuals known to be allergic to bacterial lysates and their excipients.\n10. Special populations: pregnant or breastfeeding women, or participants of childbearing age who do not intend to use contraception during the trial.\n11. Other: Participants who have taken part in other clinical trials involving medicinal products within the past 30 days; or where the investigator considers that there is poor compliance, a mental health condition, or any other circumstance rendering the participant unsuitable for the trial.","ALL","65 Years",{"count":57,"type":22},132,"OBSERVATIONAL","A Prospective Clinical Study on the Efficacy and Safety of Bacterial Lysate (OM-85) Combined with Antihistamines in the Treatment of Chronic Spontaneous Urticaria (CSU): A Single-Centre, Observational, Cohort Study",[61],"Chronic Spontaneous Urticaria (CSU)","NOT_YET_RECRUITING","2026-05-04",{"date":65,"type":38},"2026-05-07",{"date":67,"type":22},"2026-05-01",{"date":69,"type":22},"2027-06-01",{"name":44,"class":45},{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100634863","phase-2-efficacy-and-safety-of-skb264-plus-anlotinib-in-egfr-tki-resistant-advanced-nsclc-with-liver-metastasis-100634863","NCT07545213","Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis","Inclusion Criteria:\n\nTo be eligible for this study, participants must meet all of the following criteria:\n\n1. Aged ≥ 18 years, both male and female;\n2. ECOG performance status score of 0-1;\n3. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) that is locally advanced (stage IIIB\u002FIIIC) or metastatic (stage IV) and not amenable to curative surgery and\u002For curative radiotherapy (with or without concurrent chemotherapy), according to the IASLC 9th edition lung cancer TNM staging system.\n4. At least one measurable target lesion in the liver (according to RECIST version 1.1);\n5. Has previously received EGFR-TKI therapy for locally advanced or metastatic NSCLC with treatment failure (radiographic disease progression)；\n6. Life expectancy ≥12 weeks.\n7. Adequate organ and bone marrow function (without receiving blood transfusion, recombinant human thrombopoietin, or colony-stimulating factor therapy within 2 weeks prior to the first dose), defined as follows:\n\n   1. Complete blood count: absolute neutrophil count (NEUT#) ≥ 1.5 × 10⁹\u002FL; platelet count (PLT) ≥ 100 × 10⁹\u002FL; hemoglobin ≥ 9 g\u002FdL;\n   2. Liver function: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≤ 2.5 × upper limit of normal (ULN); total bilirubin (TBIL) ≤ 1.5 × ULN;\n   3. Renal function: creatinine clearance (Ccr) ≥ 60 mL\u002Fmin (Cockcroft-Gault formula see appendix);\n   4. Cardiac function: left ventricular ejection fraction (LVEF) ≥ 50% as assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan;\n8. Female participants of childbearing potential and male participants with partners of childbearing potential must use a medically approved contraceptive method (e.g., intrauterine device, contraceptive pills, or condoms) during the study treatment period and for 6 months after the last dose;\n9. Participants voluntarily enroll in this study, sign the informed consent form, have good compliance, and cooperate with follow-up visits.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will not be enrolled in this study:\n\n1. Histologically or cytologically confirmed presence of small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components;\n2. Previous treatment with TROP2-targeted therapy and\u002For topoisomerase I inhibitors;\n3. Has had other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin;\n4. Known or screening-detected symptomatic active central nervous system (CNS) metastases or carcinomatous meningitis (Note: ① Patients who have been treated and have stable disease for ≥4 weeks and have discontinued systemic corticosteroids (at any dose) for \\>3 days may be enrolled. ② Patients with asymptomatic brain metastases (i.e., no neurological symptoms, no requirement for corticosteroids, and no lesion \\>1.5 cm) are eligible but require regular brain imaging as part of disease site evaluation)；\n5. Known history of allergy to the study drugs or their components, history of immunodeficiency, or history of organ transplantation;\n6. History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment; current ILD or non-infectious pneumonitis; or suspected ILD or non-infectious pneumonitis that cannot be ruled out by imaging at screening; clinically severe pulmonary impairment due to concurrent pulmonary diseases, including but not limited to any underlying pulmonary disease (e.g., pulmonary embolism within 3 months prior to dosing, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.) or any autoimmune, connective tissue, or inflammatory disease that may affect the lungs (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.), or prior pneumonectomy;\n7. Active infection requiring systemic therapy within 2 weeks prior to the first dose;\n8. According to the investigator's judgment, presence of concomitant diseases that seriously jeopardize patient safety or affect the patient's ability to complete the study, including but not limited to hypertension uncontrolled by medication, severe diabetes, active infection, etc;\n9. Occurrence of arterial\u002Fvenous thrombotic events, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism, within 12 weeks prior to signing the informed consent form;\n10. Current active bleeding, or central lung cancer with potential for massive hemorrhage; or history of bleeding disorders (e.g., von Willebrand disease or hemophilia); clinically significant bleeding within 6 months prior to enrollment (e.g., gross hematuria, gastrointestinal bleeding, and hemoptysis); or receipt of therapeutic anticoagulants or aspirin within 14 days prior to enrollment;\n11. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or minor surgical procedure within 7 days prior to enrollment;\n12. Documented severe dry eye syndrome, severe meibomian gland disease and\u002For blepharitis, or a history of corneal disease that prevents or delays corneal healing;\n13. Any other conditions that, in the investigator's opinion, make the patient unsuitable for participation in this study.",{"count":78,"type":22},27,[80],"PHASE2","The goal of this clinical trial is to learn if the combination therapy with SKB264 and anlotinib works to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC). It will also learn about the safety of the combination therapy with SKB264 and anlotinib. The main questions it aims to answer are:\n\nDoes combination therapy with SKB264 and anlotinib increase response rate and disease control rate, prolong duation of response and progressioin-free survival.\n\nWhat medical problems do participants have when taking combination therapy with SKB264 and anlotinib? Researchers will compare combination therapy with SKB264 and anlotinib to a historical data (the response rate of other drugs reported in literature) to see if combination therapy with SKB264 and anlotinib works better to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC).\n\nParticipants will:\n\n1. receive SKB264 4 mg\u002Fkg intravenously on a 14-day cycle, and take anti-H1\u002FH2 antihistamines, acetaminophen, and dexamethasone is recommended before infusion for the first 4 infusions to prevent side effects; the regimen may be simplified starting from the 5th infusion.\n2. take anlotinib 10 mg orally once daily for 14 consecutive days, followed by a 7-day rest period.\n3. Visit the clinic once every week for checkups and tests",[83,84],"Non-small Cell Lung Cancer","EGFR Mutant Advanced Non-small Cell Lung Cancer",[86,87,88,89,90],"non-small cell lung cancer","NSCLC","EGFR-TKI resistance","SKB264","anlotinib","2026-04-16",{"date":93,"type":38},"2026-04-22",{"date":95,"type":22},"2026-04-20",{"date":97,"type":22},"2028-08-15",{"name":44,"class":45},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":55,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100616117","phase-4-rws-of-of-liraglutide-alone-and-in-combination-with-orlistat-for-weight-loss-in-overweightobese-patients-100616117","NCT07301437","RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight\u002FObese Patients.","A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight\u002FObese Patients.","Inclusion Criteria:\n\n* BMI: ≤ 35 kg\u002Fm² and ≥ 30 kg\u002Fm², or ≥ 27 kg\u002Fm² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)\n* Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.\n* No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.\n\nExclusion Criteria:\n\n* Allergy to liraglutide, orlistat or excipients\n* Severe liver and kidney dysfunction: ALT or AST\\> three times the upper limit of normal, or eGFR \\\u003C30 mL\u002Fmin\n* Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism\u002Fhypothyroidism\n* Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers\n* Pregnant or lactating women\n* Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).",{"count":107,"type":22},120,[109],"PHASE4","To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight\u002Fobese patients.",[112],"Overweight and Obese Adults","2026-03-20",{"date":115,"type":38},"2026-03-23",{"date":67,"type":22},{"date":118,"type":22},"2027-08-31",{"name":44,"class":45},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":138,"leadSponsor":139,"locationsCount":4},"100615218","phase-4-the-effect-of-alogliptin-combined-with-actoplus-met-on-glucose-and-lipid-metabolism-and-pancreatic-function-in-patients-with-t2dm-complicated-with-mafld-100615218","NCT07289750","The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD","The Effect of Alogliptin Combined With Pioglitazone and Metformin Hydrochloride Tablets on Glucose and Lipid Metabolism and Islet Function in Patients With Type 2 Diabetes Mellitus Complicated With Metabolic Dysfunction-associated Fatty Liver Disease","Inclusion Criteria:\n\n* Clinical diagnosis of T2DM\n* Clinical diagnosis of MAFLD\n* HbA1c: 6.5-9.5%\n* BMI: 19-35 kg\u002Fm2\n* No hypoglycemic drugs or insulin have been used within half a year\n\nExclusion Criteria:\n\n* Severe infections, surgeries and other emergency\n* Other types of diabetes\n* Severe cardiovascular, brain, liver and kidney disorders\n* Malignant tumor","75 Years",{"count":21,"type":22},[109],"To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.",[132,133],"T2DM","MAFLD",[132,133],{"date":136,"type":38},"2026-03-24",{"date":67,"type":22},{"date":118,"type":22},{"name":44,"class":45},{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":46},"100619362","the-efficacy-and-safety-of-anti-inflammation-treatment-hirudoid-introduction-followed-by-yellow-light-therapy-combined-with-tofacitinib-and-doxycycline-in-chinese-adult-patients-with-mild-to-moderate-erythematous-telangiectatic-rosacea-100619362","NCT07343635","The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea","The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea: A Prospective Parallel Controlled Single-blind Cohort Study","Inclusion Criteria:\n\n* The subjects are male or female, aged 18 to 70 years (inclusive); they voluntarily participate in this study and sign the informed consent form.\n* They are diagnosed with erythematous telangiectatic rosacea, meeting the diagnostic criteria in the \"Chinese Guidelines for the Diagnosis and Treatment of Rosacea (2021)\".\n* At screening and baseline, the IGA score is 2 (mild) or 3 (moderate).\n* The subjects agree not to use any other rosacea treatment drugs (prescription or over-the-counter) during the study period.\n* The subjects are willing to minimize external factors that may trigger rosacea (such as spicy food, alcoholic beverages, prolonged sun exposure, etc.).\n* The subjects (including their partners) agree that they have no plans to conceive within 3 months after signing the informed consent form until the end of the last treatment and are willing to take effective contraceptive measures voluntarily.\n\nExclusion Criteria:\n\n* Diagnosed as papulopustular, hypertrophic, ocular rosacea or other special types of rosacea\n* Other facial skin diseases that were active during the screening period or baseline may interfere with the efficacy\u002Fsafety assessment of erythematous vasodilating rosacea, including but not limited to perioral dermatitis, facial keratosis, seborrheic dermatitis, and acne vulgaris. If the above-mentioned skin diseases were in clinical remission both during the screening period and at baseline, and the investigators determined that they would not affect the assessment of this study, they could be included.\n* Subjects who have underlying known diseases or medical conditions, or who have undergone major surgeries within the six months prior to screening, where, based on the researcher's judgment, the subjects are at risk (such as cancer, leukemia or cachexia in the blood system);\n* During the screening period or at baseline, researchers evaluate abnormal laboratory test results with significant clinical significance;\n* Those who have received LED light therapy for their faces in the past two weeks;\n* Those who have received laser, intense pulsed light (IPL), fractional microneedle radiofrequency treatment, CO2 exfoliating fractional laser treatment, electrocoagulation, dermabrasion, chemical peels, or any facial procedures (such as Thermage, etc.) for facial treatment in the past 6 weeks;\n* Facial active infections who are currently receiving or require systemic treatment (systemic antibiotics, antifungal, antiviral drugs) - including bacterial pustules, fungal folliculitis, herpeder-like skin lesions and massive proliferation of Demodex mites;\n* Local\u002Fsystemic treatment that did not complete an adequate elution period before baseline, including: Glucocorticoids (corticosteroids), calcineurin inhibitors (such as tacrolimus, pimecrolimus), Janus kinase inhibitors, epidermal growth factors (such as commercially available repair dressings containing recombinant human EGF), acne treatment drugs (such as azelaic acid, retinoids, benzoyl peroxide, traditional Chinese medicine\u002FChinese patent medicine treatment), Such as tanshinone, metronidazole tablets, etc.), immunomodulators, topical astringents\u002Fexfoliating products, antibiotics (such as macrolides, metronidazole), high-concentration vitamin A (10,000 units per day), anti-pruritus drugs (such as antihistamines), etc.\n* Use drugs that cause acne-like rashes simultaneously (such as azathioprine, haloperidol, halogens, lithium, systemic corticosteroids, phenytoin sodium, phenobarbital, testosterone, anabolic steroids, isoniazid);\n* Those who have used astringents\u002Fexfoliating products (cleansing or exfoliating products containing salicylic acid or alcohol) within the past 2 days or are planned to use them during the study period;\n* The subject has a history of alcohol abuse (drinking more than 14 units) within the past 2 years or a history of drug abuse within the past 5 years;\n* Individuals infected with human immunodeficiency virus (HIV), those in the active stage of hepatitis C virus (HCV) infection (positive for anti-HCV), or those in the active stage of hepatitis B virus (HBV) infection (HBV-DNA \\> 2000IU\u002FmL or 104 copies \u002Fml), or those with positive Treponema pallidum antibodies showing an active stage of infection;\n* Female subjects who plan to become pregnant or breastfeed during the study period;\n* Those who are sensitive to light or use photosensitive drugs;\n* People who are allergic to Hirudoid, tofacitinib, doxycycline, hydroxychloroquine or their ingredients.","70 Years",{"count":149,"type":22},186,[25],"The efficacy and safety of anti-inflammation treatment (Hirudoid introduction followed by yellow light therapy) combined with tofacitinib and doxycycline in Chinese adult patients with mild to moderate erythematous telangiectatic rosacea: A prospective parallel controlled single-blind cohort study",[153],"Erythematotelangiectatic Rosacea",{"date":136,"type":38},{"date":156,"type":38},"2026-02-01",{"date":158,"type":22},"2027-07-01",{"name":44,"class":45},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":127,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100623317","phase-2-a-clinical-study-on-the-treatment-of-metastatic-colorectal-cancer-at-the-second-line-or-beyond-100623317","NCT07395063","A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","A Single-arm, Open-label Clinical Study of Irinotecan Liposome Combined With Capecitabine, Bevacizumab and Camrelizumab as Second-line or Higher Treatment for Patients With Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* Patients pathologically diagnosed with colorectal cancer;\n* Received systemic treatment on the first line;\n* Age: 18 to 75 years old, gender not limited.\n* There must be at least one measurable lesion as the target lesion (in accordance with the RECIST v1.1 standard);\n* ECOG: 0-1;\n* Expected survival period ≥3 months;\n* Women of childbearing age must undergo a blood pregnancy test within 3 days before randomization, and the result must be negative. They must also be willing to take appropriate contraceptive measures during the trial and for 6 months after the end of treatment. For men, it should be agreed to use appropriate methods of contraception during the study period and within 3 months after the end of treatment;\n* The subjects voluntarily joined this study and signed the informed consent form.\n\nExclusion Criteria:\n\n* Patients with wild-type RAS and BRAF, whose primary lesion is located in the left colorectal tract, but who have not received cetuximab as the first-line treatment\n* Patients with advanced colorectal cancer who have MSI-H or dMMR\n* Those with a history of other malignant diseases in the last five years, except for cured skin cancer and cervical carcinoma in situ\n* For patients with a history of uncontrolled epilepsy, central nervous system diseases or mental disorders, the researcher will determine that the clinical severity may prevent them from signing the informed consent form or affect their compliance with oral medication\n* Clinically severe (i.e., active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) grade II or more severe congestive heart failure, or severe arrhythmia requiring drug intervention (see Appendix 12), or a history of myocardial infarction within the last 12 months\n* Those who need immunosuppressive therapy for organ transplantation\n* Severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases\n* The baseline blood routine and biochemical indicators of the subjects did not meet the following criteria: hemoglobin ≥90g\u002FL; The absolute neutrophil count (ANC) is ≥1.5×109\u002FL; Platelet count ≥100×109\u002FL; ALT and AST≤2.5 times the normal upper limit value; ALP≤2.5 times the normal upper limit value; Serum total bilirubin \\\u003C1.5 times the normal upper limit value; Serum creatinine \\\u003C1 times the upper limit of normal; Serum albumin ≥30g\u002FL\n* Those known to have a deficiency of dihydropyrimidine dehydrogenase (DPD)\n* Those who are allergic to any investigational drug ingredients (such as irinotecan, irinotecan liposome, capecitabine, bevacizumab and camrelizumab)\n* Pregnant or breastfeeding women\n* Have received any of the following treatments:\n\nThe concomitant medication contained CYP3A4, CYP2C8 strong suppressor\u002Fstrong inducer or UGT1A1 strong suppressor within 2 weeks prior to randomization;Use immunosuppressants or systemic hormones for immunosuppressive purposes within 2 weeks before randomization (dose \\>10mg\u002F day, prednisone or other equivalent therapeutic hormones); \\\u003Cs:1\\> Received radiotherapy within 2 weeks prior to randomization;Undergo major surgeries (such as thoracotomy, laparotomy, etc.) within 4 weeks before randomization;The patient has received any other clinical study drug treatment within 4 weeks prior to randomization, unless it is an observational (non-interventional) clinical study or follow-up of an interventional clinical study.\n\n\\- Abnormal coagulation function, with a bleeding tendency, or currently undergoing thrombolytic or anticoagulant therapy. Prophylactic use of low-dose aspirin (≤100mg\u002F day) and low-molecular-weight heparin (enoxaparin 40mg\u002F day and other low-molecular-weight heparin at equivalent doses) is permitted.",{"count":168,"type":22},68,[80],"A single-arm, open-label clinical study of irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab as second-line or above treatment for patients with metastatic colorectal cancer, aiming to evaluate the efficacy and safety of irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab as second-line or above treatment for patients with metastatic colorectal cancer The medication regimen is irinotecan liposome (II) + capecitabine + bevacizumab + camrelizumab until disease progression or intolerable toxicity.",[172],"Metastatic Colorectal Cancer (CRC)",[174,175],"Metastatic colorectal cancer of stage ll or higher","The treatment regimen of irinotecan liposome combined with capecitabine and camrelizumab","2026-02-03",{"date":178,"type":38},"2026-02-09",{"date":156,"type":22},{"date":181,"type":22},"2029-02-01",{"name":44,"class":45},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":4},"100621840","application-of-electrical-impedance-tomography-in-evaluating-pulmonary-function-improvement-after-high-lateral-recumbent-position-therapy-in-ards-patients-100621840","NCT07375849","Application of Electrical Impedance Tomography in Evaluating Pulmonary Function Improvement After High Lateral Recumbent Position Therapy in ARDS Patients","Inclusion Criteria:\n\n1. Age \\>= 18 years.\n2. Diagnosis of ARDS according to the Berlin Definition (2023 update).\n3. Clinically evaluated as suitable for positional therapy by physicians.\n4. Signed informed consent obtained from the patient or legal representative.\n5. Absence of severe spinal deformities or musculoskeletal disorders that may compromise safe high lateral positioning.\n6. No severe skin conditions (e.g., extensive open wounds or pressure ulcers) that may affect the feasibility of lateral positioning.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Severe cardiac diseases (e.g., unstable arrhythmia or heart failure) that may worsen with positional changes.\n3. Severe coagulation disorders with increased bleeding risk.\n4. Known allergy to the EIT device or any of its components.\n5. Severe psychiatric disorders impairing study compliance.\n6. Current participation in experimental therapies that may affect pulmonary function.\n7. Severe active infections requiring special isolation measures.\n8. Anticipated need for emergency surgery or life-threatening complications within 24 hours.",{"count":190,"type":22},140,[25],"This randomized controlled trial investigates the effects of prone positioning versus lateral positioning at different angles (30°, 90°, 120°) on pulmonary function improvement in patients with acute respiratory distress syndrome (ARDS). Utilizing electrical impedance tomography (EIT) technology, the study monitors key parameters including ventilation distribution and ventilation-perfusion matching in real time, while integrating respiratory mechanics and blood gas analysis data to comprehensively evaluate the therapeutic efficacy of positional adjustments. The study hypothesizes that high-angle lateral positioning may reduce adverse complications associated with prone positioning while effectively improving oxygenation and pulmonary function. The ultimate objective is to provide a safer and more personalized positional therapy regimen for clinical practice, optimizing ARDS treatment strategies to reduce mortality and enhance patient survival outcomes.",[194],"Acute Respiratory Distress Syndrome (ARDS)","2026-01-22",{"date":197,"type":38},"2026-01-29",{"date":199,"type":22},"2026-01-01",{"date":201,"type":22},"2027-12-01",{"name":44,"class":45},{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100621841","phase-2-investigating-the-clinical-benefits-and-underlying-mechanisms-of-danhong-injection-in-modulating-mitochondrial-homeostasis-against-sepsis-associated-myocardial-dysfunction-100621841","NCT07375862","Investigating the Clinical Benefits and Underlying Mechanisms of Danhong Injection in Modulating Mitochondrial Homeostasis Against Sepsis-Associated Myocardial Dysfunction","Inclusion Criteria:\n\n1. Patients who met the Sepsis-3 criteria, defined by a suspected or confirmed infection and an increase in the Sequential Organ Failure Assessment (SOFA) score of 2 points or more from baseline.\n2. Patients with a diagnosis of sepsis-induced myocardial dysfunction (SIMD).\n\nExclusion Criteria:\n\n1. Patients with significant primary cardiac diseases, including unstable coronary artery disease, severe cardiomyopathy, or severe valvular heart disease.\n2. Exclusion criteria included long-term use of Danhong Injection or recent use of other medication with potential significant impact on cardiac function.\n3. Patients with severe hepatic dysfunction (defined as Child-Pugh class C) or severe renal insufficiency (defined as creatinine clearance \\\u003C30 mL\u002Fmin) were excluded.\n4. Patients with a known allergy to any component of Danhong Injection or a history of severe allergic diathesis were excluded.\n5. Pregnant or lactating women\n6. Patients with severe mental illness or inability to cooperate with the study.\n7. Participation in other drug clinical trials within 3 months prior to enrollment.",{"count":190,"type":22},[80],"This study aims to evaluate the clinical efficacy of Danhong injection in patients with septic myocardial injury through a prospective randomized controlled trial. The study will enroll 140 patients meeting criteria for septic myocardial injury, divided into a Danhong injection group and a placebo group. Primary endpoints include changes in myocardial injury markers and improvement rates in cardiac function over 7 days, while secondary endpoints include 28-day mortality rates. This will determine whether Danhong injection possesses myocardial protective effects and provide evidence-based support for expanding its clinical indications.",[213],"Sepsis-Induced Myocardial Dysfunction",{"date":197,"type":38},{"date":216,"type":22},"2026-07-01",{"date":218,"type":22},"2028-12-01",{"name":44,"class":45},{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":54,"minAge":226,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":46},"100621569","a-study-on-the-effect-of-electronic-moxibustion-based-on-ziwu-liuzhu-in-treating-constipation-in-stroke-patients-100621569","NCT07372326","A Study on the Effect of Electronic Moxibustion Based on Ziwu Liuzhu in Treating Constipation in Stroke Patients","Inclusion criteria:\n\n1. Meets the diagnostic criteria of both Western medicine and traditional Chinese medicine, and has not undergone surgery or other internal medical treatments, with the occurrence of constipation;\n2. The condition is stable, without severe clinical complications;\n3. Can accept moxibustion treatment, and the local skin is undamaged;\n4. Those who agree to participate in this study and sign the informed consent form.\n\nExclusion criteria:\n\n1. Digestive tract disorders, such as intestinal polyps, tuberculosis, and tumors. Irritable bowel syndrome or constipation secondary to organic diseases (such as endocrine, metabolic or post-operative diseases); abdominal aneurysm, hepatosplenomegaly, or severe cardiovascular, liver, kidney or mental disorders and coagulation disorders.\n2. The patient had constipation before the stroke.\n3. The patient withdrew from the study due to other reasons during the course of the study.\n\nDropout criteria and termination criteria:\n\n1. Patients who have not received the prescribed treatment and whose therapeutic effect cannot be determined;\n2. Patients who experience serious adverse events or complications and are not suitable to continue the treatment and thus the trial is terminated;\n3. Patients with poor compliance, who withdraw from the treatment during the course of the trial, or who use treatment methods prohibited by this protocol concurrently, or who change the treatment method halfway on their own.\n\nNote: For any patient meeting any of the above criteria 1, they will be handled as a dropout case.","30 Years","80 Years",{"count":229,"type":22},105,[25],"This study aims to explore the application effect of Ziwu Liuzhu electronic moxibustion combined with auricular points on constipation in stroke patients through clinical controlled trials, as well as the advantages over using electronic moxibustion alone.",[233],"Stroke Patients With Constipation",[235,236,237,238],"cerebral hemorrhage","constipation","midnight-midday ebb flow","electronic moxibustion","2026-01-19",{"date":241,"type":38},"2026-01-28",{"date":243,"type":38},"2025-05-15",{"date":245,"type":22},"2026-10-30",{"name":44,"class":45},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":17,"sex":54,"minAge":254,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":46},"100620121","mir-342-5pankg-pathway-in-early-ad-synaptic-dysfunction-100620121","NCT07353502","miR-342-5p\u002FAnkG Pathway in Early AD Synaptic Dysfunction","Effects of miR-342-5p\u002FAnkG Pathway-Mediated Axon Initial Segment Filtering Injury on Early Synaptic Dysfunction in Alzheimer's Disease and Its Clinical Applications","Inclusion Criteria:\n\nInclusion criteria for AD group:\n\n1. Meet the diagnostic criteria for \"probable AD dementia\" established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)\n2. MMSE score between 0-23 points, Clinical Dementia Rating (CDR) score ≥0.5 points, Hachinski Ischemic Score \\\u003C4 points\n3. Brain MRI showing bilateral temporal lobe and hippocampal atrophy\n4. Age ≥50 years\n\nInclusion criteria for control group:\n\n1. Healthy subjects with age matched to the AD group\n2. Normal cognitive function and good activities of daily living\n3. No dementia patients among first-degree relatives\n4. Negative brain MRI and neurological examination\n\nExclusion Criteria:\n\n1. Dementia or cognitive impairment caused by other diseases\n2. History of substance abuse\n3. Progressive primary aphasia\n4. Previous traumatic brain injury\n5. Patients with comorbid depression, schizophrenia, or severe diseases of the cardiovascular, hepatic, renal, or hematological systems\n6. Impaired consciousness and inability to cooperate\n7. Other conditions unsuitable for inclusion","50 Years",{"count":256,"type":22},40,[25],"Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. Investigators' previous research discovered that in the brains of diseased mice, certain special substances (the miR 342 5p\u002FAnkG-mediated pathway) might be related to this abnormality, and these substances can be detected in both blood and cerebrospinal fluid. Therefore, investigators want to further explore the specific mechanisms of abnormal nerve cell connections, seek biomarkers for early detection of the disease, and provide new ideas for early diagnosis in the future.",[260,261],"Alzheimer Disease","Biomarker in Early Diagnosis","2026-01-18",{"date":264,"type":38},"2026-01-20",{"date":266,"type":38},"2025-06-20",{"date":268,"type":22},"2026-03-10",{"name":44,"class":45},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":289,"leadSponsor":291,"locationsCount":4},"100620840","construction-and-application-of-the-whole-course-management-scheme-for-knee-arthroscopic-ligament-surgery-patients-based-on-internet--100620840","NCT07362849","Construction and Application of the Whole Course Management Scheme for Knee Arthroscopic Ligament Surgery Patients Based on \"Internet +\"","Inclusion Criteria:\n\nOrthopedic knee arthroscopic ligament surgery patients; Age range: 18-60 years old; Informed consent from participants in this study; Internet is available at home, and patients and their families can skillfully use mobile WeChat and other functions.\n\nExclusion Criteria:\n\nThose who give up halfway or have difficulty cooperating to complete the exercise; I am currently participating in other clinical trials that may have an impact on this study; Having a clear history of mental illness and epilepsy in the past; Postoperative complications such as fractures and rheumatoid arthritis (such as thrombosis or osteomyelitis) are present; Lower extremity deep vein thrombosis;","60 Years",{"count":278,"type":22},60,[25],"On the basis of the conventional diagnosis and treatment mode, the experimental group added an application program for closed-loop management of the entire course of the disease. Within 24 hours of admission, orthopedic specialist nurses conducted personal evaluations of patients, mainly observing their level of importance for postoperative functional exercise, compliance with patients and their families, intention towards the application program, setting personalized goals, providing health guidance, and improving patients' awareness of rehabilitation needs. Teach patients to proficiently use the program's educational video viewing function, function exercise video classification query, upload function exercise videos, view medical feedback, and pay attention to questionnaire filling for in-hospital and post hospital health management. During home stay, orthopedic specialist nurses and rehabilitation therapists conduct weekly assessments of exercise compliance and functional status in patient uploaded videos. Motivational measures are taken for patients with high cooperation to promote goal achievement. Patients with negative and fatigue attitudes seek professional psychological counseling and provide successful rehabilitation cases to enhance patient confidence. Patients who have doubts during the rehabilitation period outside the hospital can apply the \"online information sending mode, online consultation+offline service\" in the program. Nurses can help patients register and authenticate, teach them how to use \"Zhe Li Nursing Home Service\" and place orders online. Orthopedic specialist nurses or rehabilitation therapists can contact the supervising doctor to communicate the patient's needs and provide relevant nursing and rehabilitation technical services on-site. The management backend has functions such as full process traceability of service behavior, workload analysis, and nurse service evaluation. It regularly updates disease-related knowledge within the program, perioperative health education, postoperative functional exercise and intervention measures, and regular functional exercise time reminders. Multi terminal collaboration implements information system integration, establishes a complete electronic health record, and forms a closed-loop management mode throughout the process.",[282],"Patients Undergoing Knee Arthroscopic Ligament Surgery",[284],"Construction and application of \"Internet plus\" full course management model in patients undergoing knee arthroscopic ligament surgery","2026-01-14",{"date":287,"type":38},"2026-01-23",{"date":199,"type":22},{"date":290,"type":22},"2027-12-30",{"name":44,"class":45},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":298,"minAge":254,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":301,"briefSummary":302,"conditions":303,"keywords":306,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":46},"100620415","phase-4-a-clinical-observation-study-of-a-chinese-patent-medicine-combined-with-tamsulosin-in-improving-sleep-and-nocturia-symptoms-after-enucleation-of-the-prostate-100620415","NCT07357324","A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate","Inclusion Criteria:\n\n* Male patients aged 50 years or older\n* History of transurethral holmium laser enucleation of the prostate (HoLEP)\n* Nocturia frequency ≥2 times per night\n* Documented bladder outlet obstruction\n* Presence of postoperative urinary incontinence and urgency symptoms\n* Ability to understand study procedures and provide written informed consent\n* Willingness to complete all scheduled follow-up visits and assessments\n\nExclusion Criteria:\n\n* Known hypersensitivity or intolerance to tamsulosin hydrochloride, Lingze tablets, or any component of these medications\n* Active malignancy or severe cancer requiring treatment\n* Cognitive impairment, psychiatric disorder, or language barrier that prevents understanding of study requirements or completion of questionnaires\n* Severe multi-organ failure or dysfunction that would interfere with study participation\n* Previous enrollment in conflicting clinical trials within the past 30 days\n* Inability to comply with the medication regimen or study protocol","MALE",{"count":300,"type":22},136,[109],"This study will test whether a traditional Chinese medicine called Lingze tablets, when added to the standard drug tamsulosin, can better improve sleep and nighttime urination problems in men after prostate surgery.\n\nWho can participate? Men aged 50 years or older who have had transurethral holmium laser enucleation of the prostate (a minimally invasive surgery for enlarged prostate) and continue to have bothersome nighttime urination (at least 2 times per night) and other urinary symptoms may be eligible.\n\nWho cannot participate? Men who cannot tolerate the study medications, have severe cancer, serious organ failure, or have conditions that prevent them from understanding or following the study requirements.\n\nWhat will participants do?\n\nAbout 136 participants will be randomly assigned (by chance, like a coin flip) to one of two groups:\n\nGroup 1: Take tamsulosin sustained-release capsule once daily for 8 weeks Group 2: Take tamsulosin sustained-release capsule once daily PLUS Lingze tablets (4 tablets, three times daily) for 8 weeks Participants will visit the hospital clinic at the start of the study, at 4 weeks, and at 8 weeks for assessments.\n\nWhat will be measured?\n\nResearchers will measure:\n\nHow many times you wake up at night to urinate Overall sleep quality using standard questionnaires Prostate symptom scores and quality of life Urine flow tests (non-invasive) Anxiety levels Any side effects or adverse events from the medications Why is this study important? Many men continue to have nighttime urination and poor sleep even after prostate surgery, which can greatly reduce quality of life. This study will help determine if combining Lingze tablets with standard treatment provides better relief than standard treatment alone.\n\nRisks and Benefits:\n\nPotential benefits: Improved sleep, fewer nighttime bathroom trips, better urinary symptoms, and enhanced quality of life.\n\nPotential risks: Possible side effects include dizziness, headache, nausea, or stomach upset from the medications. All participants will be closely monitored for any problems and can contact the study team 24\u002F7 with concerns.\n\nPrivacy:\n\nAll personal and medical information will be kept confidential and used only for research purposes in accordance with hospital and national regulations.",[304,305],"Benign Prostatic Hyperplasia","Nocturia Associated With Nocturnal Polyuria",[304,307,308,309],"Transurethral Holmium Laser Enucleation of Prostate","Tamsulosin","Lingze Tablets","2026-01-13",{"date":195,"type":38},{"date":313,"type":38},"2024-12-01",{"date":315,"type":22},"2026-12-31",{"name":44,"class":45},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":54,"minAge":226,"maxAge":55,"enrollmentInfo":324,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":4},"100618760","impact-of-abc-x-model-nursing-on-psychological-resilience-and-family-function-in-tka-patients-100618760","NCT07335809","Impact of ABC-X Model Nursing on Psychological Resilience and Family Function in TKA Patients","Study on the Impact of Nursing Interventions Based on the ABC-X Model on Psychological Resilience and Family Functioning in Patients After Total Knee Arthroplasty","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for knee osteoarthritis as outlined in the Guidelines for Diagnosis and Treatment of Osteoarthritis (2018 Edition)\\[6\\], with confirmation by imaging examination;\n2. Age 30-65 years;\n3. Meet the surgical indications of our hospital and be a first-time candidate for unilateral TKA;\n4. Normal neurological and cognitive function, with stable vital signs;\n5. Family members have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of lower limb movement impairments;\n2. Accompanied by severe complications;\n3. Infectious diseases or severe immune system disorders;\n4. Other acute and critical illnesses;\n5. History or presence of mental dysfunction;\n6. Language or communication disorders.",{"count":325,"type":22},117,"The ABC-X model is a systematic intervention approach based on stress source analysis and adaptation theory. It emphasizes the dynamic interaction between stressors (A), coping resources (B), cognitive appraisal (C), and crisis outcomes (X). By systematically assessing patients' psychosocial stress, integrating family and social support resources, and optimizing disease cognition, it helps patients and their families alleviate psychological pressure and cope with disease challenges. This study aims to explore the impact of nursing interventions based on the ABC-X model on coping styles and family functioning in patients after total knee arthroplasty.",[328],"Total Knee Arthroplasty","2026-01-12",{"date":310,"type":38},{"date":332,"type":22},"2025-12-20",{"date":334,"type":22},"2028-12-30",{"name":44,"class":45},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":17,"sex":54,"minAge":344,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":358,"locationsCount":46},"100619619","investigation-into-the-dynamic-variations-of-end-tidal-carbon-monoxide-concentration-etcoc-in-neonates-utilizing-non-dispersive-infrared-spectroscopy-and-its-implications-for-jaundice-management-100619619","NCT07346976","Investigation Into the Dynamic Variations of End-Tidal Carbon Monoxide Concentration (ETCOc) in Neonates Utilizing Non-Dispersive Infrared Spectroscopy and Its Implications for Jaundice Management","Investigation Into the Dynamic Variations of End-Tidal Carbon Monoxide Concentration (ETCOc) in Neonates Utilizing Non-Dispersive Infrared Spectroscopy and Its Implications for Jaundice Management.","ETCO","Inclusion Criteria:\n\n1. Newborns with gestational age of ≥ 37 weeks and birth weight of ≥ 2.5 kg;\n2. Newborns delivered by either vaginal delivery or cesarean section and with hospital stay of ≥ 3 days.\n\nExclusion Criteria:\n\n1. History of second-hand smoke exposure within 24 hours\n2. Parents smoke or are exposed to second-hand smoke.","0 Days","28 Days",{"count":347,"type":22},100,[25],"The objective of this study is to ascertain the diagnostic threshold of end-tidal carbon monoxide (ETCOc, adjusted for ambient CO levels) within the first three days postpartum, stratified by neonatal age at birth. Additionally, the study aims to evaluate the concordance of the risk range of ETCOc, as measured by non-dispersive infrared spectroscopy, with existing literature, and to assess the reliability of this technology in the management of neonatal hyperbilirubinemia.",[351],"Neonatal Hyperbilirubinemia","2026-01-08",{"date":354,"type":38},"2026-01-16",{"date":356,"type":38},"2025-12-05",{"date":158,"type":22},{"name":44,"class":45},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":17,"sex":54,"minAge":19,"maxAge":127,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":4},"100618843","a-study-on-the-application-of-positive-psychological-counseling-based-on-dou-bao-software-in-patients-with-post-stroke-depression-100618843","NCT07336888","A Study on the Application of Positive Psychological Counseling Based on \"Dou Bao\" Software in Patients With Post-stroke Depression","Inclusion Criteria:\n\n* Meets the criteria of either the \"Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke\" or the \"Chinese Guidelines for the Diagnosis and Treatment of Acute Cerebral Hemorrhage\" and is confirmed by CT or MRI;\n* Patients with stable vital signs and conditions;\n* Meets the \"Third Edition of the Classification and Diagnosis Criteria for Mental Disorders in China\" and has a score of ≥5 on the 9-item Patient Health Questionnaire (PHQ-9) scale;\n* Patients are over 18 years old;\n* Can understand the relevant content of the scale correctly and provide answers independently or with the help of others, have clear consciousness and sign the consent form;\n* Can use smartphones.\n\nExclusion Criteria:\n\n* Those with severe functional impairments of important organs such as the heart, lungs, liver and kidneys;\n* Those without a smart phone;",{"count":366,"type":22},240,[25],"Patients with PSD have the characteristics of high incidence rate, difficult identification and great harm. However, the existing AI chat platforms have not developed any relevant software or programs for PSD patients. Given that the chatbot function in the \"Douba\" software is relatively mature and can flexibly modify the corresponding intelligent agent according to user needs, this study intends to appropriately supplement and optimize the AI agent in the \"Douba\" software to explore the effect of the chatbot in the software in alleviating the symptoms of PSD patients.",[370,371],"Stroke","Post Stroke Depression","2026-01-07",{"date":310,"type":38},{"date":375,"type":22},"2027-01-01",{"date":377,"type":22},"2027-12-31",{"name":44,"class":45},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":276,"enrollmentInfo":386,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":394,"leadSponsor":395,"locationsCount":4},"100616641","brain-network-fmri-analysis-in-proprioceptive-training-for-chronic-low-back-pain-100616641","NCT07308249","Brain Network fMRI Analysis in Proprioceptive Training for Chronic Low Back Pain","Research on the Application of Brain Network Functional Connectivity Analysis Based on Functional Magnetic Resonance Imaging in Proprioceptive Training for Chronic Non-Specific Low Back Pain","Inclusion Criteria:\n\n* Age between 18 and 60 years old;\n\n  * Current or past low back pain lasting more than three months; ③ No abnormal sensation or reflex abnormalities in the lower limbs; ④ Able to commit to participating in training three times per week for three months.\n\nExclusion Criteria:\n\n* Fractures, dislocations, structural abnormalities, prior surgery, metal implants, or lumbar disc herniation;\n\n  * Comorbidities such as severe cardiovascular diseases, neurological disorders, osteoporosis, or metabolic diseases; ③ Low back pain caused by visceral diseases;\n\n    * VAS score (range 1-10) exceeding 8 points;\n\n      * Pregnant or lactating women; ⑥ Symptoms of nerve root irritation; ⑦ Recent participation in core stability training.",{"count":256,"type":22},"Through longitudinal analysis of dynamic changes in DMN functional connectivity before and after sensory training intervention, combined with pain behavioral and functional improvement indicators, this study systematically reveals the central neural remodeling patterns in CNLBP and establishes an objective efficacy evaluation system based on multimodal imaging.",[389],"Brain Network Functional Connectivity","2025-12-15",{"date":392,"type":38},"2025-12-29",{"date":332,"type":22},{"date":334,"type":22},{"name":44,"class":45},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":55,"enrollmentInfo":403,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":409,"leadSponsor":411,"locationsCount":4},"100616642","mechanism-of-umbilical-moxibustion-in-the-treatment-of-ibs-b-100616642","NCT07308262","Mechanism of Umbilical Moxibustion in the Treatment of IBS-b","Non-targeted Metabonomics Combined With 16S Sequencing to Analyze the Mechanism of Umbilical Moxibustion in the Treatment of IBS-B","Study Type: Prospective, single-blinded, randomized controlled trial (patient-blinded, researcher-unblinded).",{"count":278,"type":22},"Evaluate the therapeutic efficacy of umbilical moxibustion therapy for IBS. Compare and analyze the differences in gut microbiota composition and diversity between the umbilical moxibustion group and the control group based on 16S sequencing.\n\nCompare and analyze the metabolomic differences between the umbilical moxibustion group and the control group based on non-targeted metabolomics, and identify differential metabolites associated with umbilical moxibustion treatment for IBS.\n\nElucidate the role of the \"gut microbiota-metabolite\" interaction in the mechanism of umbilical moxibustion for treating IBS.",[406],"Non-targeted Metabolomics",{"date":392,"type":38},{"date":332,"type":22},{"date":410,"type":22},"2026-12-30",{"name":44,"class":45},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":426,"leadSponsor":427,"locationsCount":4},"100616650","research-on-an-intelligent-health-recommendation-system-for-chronic-disease-comorbidity-integrating-tcm-100616650","NCT07308366","Research on an Intelligent Health Recommendation System for Chronic Disease Comorbidity Integrating TCM","Research on an Intelligent Health Preservation Recommendation System for Chronic Disease Comorbidity Based on the Integration of Traditional Chinese Medicine Constitution Database and Multimodal Large Language Models","Inclusion Criteria:\n\nAge ≥ 18 years; Clear diagnosis of hypertension, type 2 diabetes, and hyperlipidemia, and a comorbid condition involving all three diseases; Stable disease condition with no recent acute complications; Capable of completing questionnaires, and willing to provide informed consent to voluntarily participate in the study.\n\nExclusion Criteria:\n\nPatients in the acute phase of the three high diseases (hypertension, diabetes, hyperlipidemia) or with severe complications (such as acute myocardial infarction or stroke); Patients with other major diseases that may affect constitution assessment or intervention implementation, such as malignant tumors, severe liver or kidney dysfunction, active tuberculosis, or mental illness; Patients who have received systematic Traditional Chinese Medicine treatment (e.g., herbal decoctions or acupuncture) within the past month, which may influence the initial assessment of constitution type; Pregnant or lactating women; Individuals unable to cooperate with measurements, with language communication barriers, or cognitive impairments; Patients participating in other interventional clinical studies.",{"count":420,"type":22},195,"1. Construct a Traditional Chinese Medicine (TCM) constitution database, clarify the distribution patterns of TCM constitution in populations with comorbid \"three-high\" conditions (hypertension, hyperlipidemia, and hyperglycemia) and their associations with metabolic indicators. Establish a \"constitution-comorbidity-metabolism\" relationship model to provide a basis for personalized intervention and the development of an AI platform.\n2. Develop the AI-HEALS system by integrating the TCM constitution database with multimodal large language models. This system will generate personalized intervention plans and provide intelligent interactive Q\\&A capabilities to enhance patient intervention adherence.\n3. Evaluate the clinical application effectiveness of the AI-HEALS system, explore the relationship between changes in constitution and intervention outcomes, and validate the TCM intervention pathway of \"regulating constitution to promote health.\" This will provide both theoretical and practical guidance for the dynamic regulation and precise intervention of TCM constitution.",[423],"TCM Constitution Theory",{"date":392,"type":38},{"date":332,"type":22},{"date":334,"type":22},{"name":44,"class":45},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":446,"locationsCount":4},"100616114","development--preliminary-validation-of-a-community-health-education-program-100616114","NCT07301398","Development & Preliminary Validation of a Community Health Education Program","Construction and Preliminary Validation of a Community Health Education Program for Patients With Interstitial Lung Disease Based on Mobile Healthcare","Inclusion Criteria:\n\nPatients diagnosed with interstitial lung disease; Aged 18 years or older; Patients who have given informed consent to participate in this study; Proficient in Chinese with no comprehension barriers; Capable of independently using internet-enabled mobile devices.\n\nExclusion Criteria:",{"count":436,"type":22},92,"This study analyzes the needs of patients regarding the content and form of home-based health education through interviews, and constructs a health education program tailored to these needs. A practical WeChat mini-program is developed to enable patients with interstitial lung disease to promptly access comprehensive health education information, consult about follow-up visits, and check test reports during their home care period, ultimately aiming to improve patients' quality of life and reduce medical consumption.",[439],"Non-neoplastic and Non-infectious Diseases","2025-12-11",{"date":442,"type":38},"2025-12-24",{"date":444,"type":22},"2025-12-30",{"date":315,"type":22},{"name":44,"class":45},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":276,"enrollmentInfo":454,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":466,"leadSponsor":468,"locationsCount":4},"100615223","construction-and-application-of-an-intelligent-collaborative-cardiac-rehabilitation-app-for-middle-aged-and-young-patients-with-myocardial-infarction-100615223","NCT07289815","Construction and Application of an Intelligent Collaborative Cardiac Rehabilitation App for Middle-aged and Young Patients With Myocardial Infarction","Construction and Application of an Intelligent Collaborative Cardiac Rehabilitation Management Model for Young and Middle-aged Patients With Myocardial Infarction Based on Intervention Mapping","Inclusion Criteria:\n\n* Patients in Ward 1 were assigned to the intervention group, and patients in Ward 2 served as the control group. The inclusion criteria were as follows: ① aged 18-60 years; ② diagnosed by cardiologists as meeting the clinical diagnostic criteria for myocardial infarction (MI) established by the Cardiology Branch of the Chinese Medical Association; ③ having basic smartphone operation skills to use the App normally; ④ providing informed consent and signing the research consent form.\n\nExclusion Criteria:\n\n* ① Complicated with severe hepatic or renal insufficiency, malignant tumors, cognitive impairment, or mental illnesses; ② Patients with NYHA class Ⅳ or definite exercise contraindications (e.g., those assessed as high-risk in exercise risk evaluation) who are unable to participate in exercise prescription intervention; ③ Patients who have difficulty completing follow-up or withdraw midway.",{"count":455,"type":22},232,[25],"This study is guided by the intervention mapping theory, combined with Fogg's behavior model and digital health technologies, focusing on the key rehabilitation obstacles and behavioral characteristics of young and middle-aged MI patients. It constructs a \"smart + collaborative\" out-of-hospital rehabilitation management model. This model, through systematic needs assessment and problem logical modeling \\[11\\], develops individualized rehabilitation paths covering multiple dimensions of intervention such as exercise, diet, medication, and psychological regulation. It relies on digital means such as mobile terminals, online education, behavior check-ins, real-time feedback, and remote follow-ups to achieve intelligent rehabilitation management. At the same time, it emphasizes the multi-disciplinary collaboration mechanism, integrating team members from cardiology, nursing, nutrition, rehabilitation, and psychology, forming a collaborative work system with information sharing, task complementarity, and consistent goals. Together, they promote the activation of patient motivation, improvement of behavioral ability, and improvement of rehabilitation compliance. The study will also verify its feasibility and initial effects in a real clinical environment, and evaluate its practical value in improving rehabilitation behaviors, promoting functional recovery, and enhancing quality of life. This study not only innovatively integrates intervention mapping and behavioral science models into the rehabilitation management of young and middle-aged MI patients in theory, filling the gap in existing rehabilitation models for this group, but also explores the path of digital rehabilitation intervention that can be promoted and replicated in grassroots clinical practice. The research results can provide practical basis for the construction of the smart rehabilitation service system under the background of \"Healthy China 2030\", and have important practical significance and social value.",[459,460,461],"Myocardial Infarction","Cardiac Rehabilitation","APP","2025-12-04",{"date":464,"type":38},"2025-12-17",{"date":199,"type":22},{"date":467,"type":22},"2028-12-31",{"name":44,"class":45},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":54,"minAge":254,"maxAge":475,"enrollmentInfo":476,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":46},"100615217","clinical-study-on-the-therapeutic-efficacy-of-biportal-endoscopic-decompression-spine-surgery-and-lumbar-decompression-fusion-surgery-in-the-treatment-of-degenerative-lumbar-spondylolisthesis-100615217","NCT07289737","Clinical Study on the Therapeutic Efficacy of Biportal Endoscopic Decompression Spine Surgery and Lumbar Decompression Fusion Surgery in the Treatment of Degenerative Lumbar Spondylolisthesis","Inclusion Criteria:\n\n1. Aged between 50 and 90 years old with a confirmed diagnosis of degenerative lumbar spondylolisthesis;\n2. Clinical symptoms include chronic pain, nerve compression, or motor dysfunction, confirmed by imaging studies (e.g., MRI or CT);\n3. No significant improvement after at least 3 months of conservative treatment (e.g., medication, physical therapy), meeting surgical indications;\n4. Understand and consent to the relevant procedures of this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients exhibiting acute spinal cord compression symptoms or requiring urgent surgical intervention;\n2. Patients with a history of spinal surgery or conditions such as spinal deformities, severe osteoporosis, or active infections that may compromise surgical outcomes;\n3. Patients with severe comorbidities affecting assessment, such as cardiovascular disease, liver or kidney failure, or uncontrolled diabetes;\n4. Patients with psychiatric disorders or cognitive impairments preventing understanding or cooperation with the study process;\n5. Patients with allergies to anesthetics or surgical equipment that may increase intraoperative risks.","90 Years",{"count":347,"type":22},"This study aims to systematically evaluate the therapeutic efficacy of dual-channel endoscopic spinal decompression versus lumbar decompression with fusion for degenerative lumbar spondylolisthesis. Patients undergoing either procedure will undergo detailed preoperative and postoperative follow-up to compare outcomes between the two techniques, specifically assessing postoperative pain relief, neurological improvement, and the incidence of surgical complications.",[479],"Lumbar Degenerative Spondylolisthesis",[481,482,479],"lumbar","ube",{"date":464,"type":38},{"date":485,"type":22},"2025-12-10",{"date":487,"type":22},"2030-06-30",{"name":44,"class":45},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":17,"sex":54,"minAge":19,"maxAge":495,"enrollmentInfo":496,"targetDuration":4,"studyType":23,"phases":497,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":505,"leadSponsor":507,"locationsCount":46},"100614789","a-study-on-the-effectiveness-of-rest-shame-interventions-based-on-cognitive-behavioural-therapy-in-reducing-social-media-addiction-100614789","NCT07284160","A Study on the Effectiveness of Rest Shame Interventions Based on Cognitive Behavioural Therapy in Reducing Social Media Addiction","Inclusion Criteria:\n\n* University students aged 18-25 who are capable of understanding and completing research-related tasks, and who have confirmed the presence of rest shaming experiences via the Rest Shaming Scale.\n\nExclusion Criteria:\n\n* Individuals with a history of severe mental illness (such as clinically diagnosed depression, anxiety disorders, etc.), cognitive impairment, or an inability to cooperate in completing the research process.","25 Years",{"count":107,"type":22},[25],"This study will employ a randomised controlled trial design to systematically intervene in university students' rest shaming through a structured intervention programme grounded in cognitive behavioural therapy (CBT), thereby examining its efficacy in reducing social media addiction. Through this research, we aim to evaluate the effectiveness of CBT interventions in alleviating rest shaming and demonstrate that operationalising rest shaming influences social media addiction.",[500],"Rest is Shameful","2025-12-03",{"date":503,"type":38},"2025-12-16",{"date":199,"type":22},{"date":506,"type":22},"2031-12-31",{"name":44,"class":45},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":17,"sex":18,"minAge":514,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":23,"phases":518,"briefSummary":519,"conditions":520,"keywords":523,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":46},"100611911","a-randomized-controlled-study-on-the-effect-of-mrjps-on-improving-ovarian-function-and-endometrial-receptivity-100611911","NCT07246733","A Randomized Controlled Study on the Effect of MRJPs on Improving Ovarian Function and Endometrial Receptivity","Inclusion Criteria:\n\n* Fertile women, aged 20 to 45 years old, with regular and normal menstrual cycles.\n\nExclusion Criteria:\n\n* ① Allergic to royal jelly or its components; ② Suffering from severe chronic diseases or endocrine system disorders; ③ Pregnant or breastfeeding; ④ Undergoing hormone replacement therapy (HRT) within the last month","20 Years","45 Years",{"count":517,"type":22},66,[25],"This study will assess the effects of the rose tablet candies produced by MRJPs on the subjects, evaluate the role of MRJPs in the ovarian function and endometrial receptivity of women, reveal the potential application value of MRJPs in reproductive health, and determine its safety and effectiveness.",[521,522],"Diminished Ovarian Reserve (DOR)","Thin Endometrium",[524,525,526,527],"Ovarian reserve","Endometrial receptivity","Major Royal Jelly Proteins（MRJPs）","Reproductive health","2025-11-20",{"date":530,"type":38},"2025-11-24",{"date":532,"type":38},"2025-07-01",{"date":534,"type":22},"2028-07-31",{"name":44,"class":45},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":514,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":23,"phases":544,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":46},"100606823","phase-1-randomized-controlled-trial-of-berberine-in-combination-with-doxycycline-in-the-treatment-of-chronic-endometritis-100606823","NCT07180563","Randomized Controlled Trial of Berberine in Combination With Doxycycline in the Treatment of Chronic Endometritis","Inclusion Criteria:\n\nDiagnosis of chronic endometritis by CD138 immunohistochemistry; Age≥ 20 years old, females of childbearing age; Agree to undergo hysteroscopy and hysteroscopic endometrial biopsy; No serious systemic disease; There are no contraindications to oral administration of doxycycline hydrochloride and berberine hydrochloride.\n\nExclusion Criteria:\n\nPatients with pregnancy status, uterine malignant disease, hormone therapy within 3 months, glucose-6 phosphate dehydrogenase deficiency, hemolytic anemia, hypersensitivity to berberine hydrochloride or doxycycline. In addition, berberine hydrochloride has fewer oral adverse reactions, occasional nausea and vomiting, rash and drug fever, which disappear after stopping the drug. If the patient takes the wrong or missed medication, it is excluded.",{"count":543,"type":22},206,[545,80],"PHASE1","Study Subjects: Eligible patients were initially diagnosed with chronic endometritis (CE) by CD138 testing through outpatient hysteroscopy. Positive CD138 expression is defined as at least one or more positive-staining plasma cells per 10 high-power fields identified as positive, and less than one positive-stained plasma cell identified as negative \\[8\\]. All patients signed an informed consent form prior to participating in the study, and the study followed the principles of the Declaration of Helsinki.\n\nInclusion Criteria: Diagnosis of chronic endometritis by CD138 immunohistochemistry; Age≥ 20 years old, females of childbearing age; Agree to undergo hysteroscopy and hysteroscopic endometrial biopsy; No serious systemic disease; There are no contraindications to oral administration of doxycycline hydrochloride and berberine hydrochloride.\n\nExclusion criteria: patients with pregnancy status, uterine malignant disease, hormone therapy within 3 months, glucose-6 phosphate dehydrogenase deficiency, hemolytic anemia, hypersensitivity to berberine hydrochloride or doxycycline. In addition, berberine hydrochloride has fewer oral adverse reactions, occasional nausea and vomiting, rash and drug fever, which disappear after stopping the drug. If the patient takes the wrong or missed medication, it is excluded.\n\nWithdrawal criteria: If the patient has corresponding adverse reaction symptoms, those with mild symptoms can be temporarily observed, and if the symptoms are severe, they can be transferred to the Department of Gastroenterology for diagnosis and treatment, and those who need to stop the drug will be withdrawn from this study.",[548],"Chronic Endometritis","2025-09-16",{"date":551,"type":38},"2025-09-18",{"date":553,"type":38},"2025-03-15",{"date":315,"type":22},{"name":44,"class":45},""]